Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Patients' Organizations Italian MS Society and its Foundation - P. Zaratin (Director of Scientific Research)

60 views

Published on

L'intervento di Paola Zaratin (Director of Scientific Research) in occasione dell'evento "Il valore della ricerca biomedica" che si è tenuto a Pula (CA) il 3 aprile 2019.

Published in: Health & Medicine
  • 1 Weird Trick To Easily Cure Vitiligo For Good In As Little As 7 Days - Guaranteed! More Info.. ●●● http://tinyurl.com/y4d5dqxj
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • If u need a hand in making your writing assignments - visit ⇒ www.HelpWriting.net ⇐ for more detailed information.
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • A Unique Easy To Follow 5-Step Plan To Eliminating Vitiligo And Related Auto-Immune Skin Disorders Using Proven Holistic Strategies. Learn More ➢➢➢ https://bit.ly/3avXuLL
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • I pasted a website that might be helpful to you: ⇒ www.WritePaper.info ⇐ Good luck!
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • You might get some help from ⇒ www.HelpWriting.net ⇐ Success and best regards!
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

Patients' Organizations Italian MS Society and its Foundation - P. Zaratin (Director of Scientific Research)

  1. 1. Patients’ Organizations Italian MS Society and its Foundation Paola Zaratin Director of Scientific Research
  2. 2. Bill of Rights ALL PEOPLE WITH MS HAVE THE RIGHT TO A RIGOROUS AND SCIENTIFIC RESEARCH OF EXCELLENCE TO DISCOVER THE CAUSES, UNDERSTAND THE MECHANISMS OF PROGRESSION AND THE POTENTIALS TO REPAIR DAMAGE, TO IDENTIFY THE POSSIBLE TREATMENTS WITH A CONCRETE IMPACT ON QUALITY' OF LIFE IN EACH PHASE OF THE DISEASE.
  3. 3. Italian MS Society: Strategic Pathway BILL OF RIGHTS MS AGENDA 2020 BAROMETER IMPACT OF RESEARCH ON PEOPLE WITH MS
  4. 4. Italian MS Society Research Strategy Map and Portfolio Zaratin P, Battaglia M.A. and Abbracchio MP, Trends in Pharmacological Sciences, 2014 – Cell Press
  5. 5.  Goals Fund promising MS treatments discovery and development research Accelerate the availability of new treatments by speeding the translation of MS research  Guiding Philosophy De-risk early stage programs, also for external partners Source opportunities globally Program selection based on parallel scientific and business assessment Fund at multiple stages (discovery, preclinical, proof of concept, and clinical trial) Italian MS Society Focus on Innovative Treatments
  6. 6. Italian MS Society Innovative Treatments: the ecosystem Ensuring expert inputs in drug discovery an development process via multidisciplinary networks Ensuring that any inventions or IP are appropriately protected if/when they are discovered Enabling “Business Development”
  7. 7. Investment in turning “high” into “low-hanging fruits Zaratin P, Battaglia M.A. and Abbracchio MP, Trends in Pharmacological Sciences, 2014 – Cell Press
  8. 8. ITALIAN MS SOCIETY RESEARCH NETWORK TO DE-RISK EARLY STAGE PROGRAMS Italian MS Society Proficiency Areas and Infrastructures DRUGS/MOLECULES CLINICAL TRIALS CENTERS DATA SHARING GENETICS IMMUNOMODULATORY MYELIN REPAIR IN VITRO & IN VIVO ACTIVITY ENABLING BIOMEDICAL AND REHABILITATION TECHNOLOGIES
  9. 9. C E N T E R S Professor Marco Salvetti ITALIAN MS SOCIETY CLINICAL PLAFORM Phase II trials in multiple sclerosis and in neurodegenerative diseases Exploratory, and experimental medicine trials REPURPOSING INITIATIVE
  10. 10. FISM 2010/R/2 Project (PI: Professor Maria Pia Abbracchio): Innovative re-myelinating strategies for multiple sclerosis via the exploitment of the new oligodendrocyte receptor GPR17 SELECT AND OVERSEE OPEN AND INTEGRATE COMMIT AND INTEGRATE GPR17 1 3 2 Understand GPR17 biology Innovative Therapies GPR17 modulators – Joint Patent Italian MS Society: GPR17 Love Story Pharma Venture capiltal
  11. 11. The "social contract" implicit in the patent system …so that others can learn from it and improve upon it! from European Patent Office Between innovation and sustainability What else is needed?
  12. 12. Next challenge: investing in high hanging fruits ‘multistakeholder collective impact’ model Source: Zaratin P, Battaglia MA, Abbracchio MP. Nonprofit foundations spur translational research. Trends Pharmacol Sci. 2014 Nov;35(11):552-5
  13. 13. Multi-Act This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under the Grant Agreement No. 787570 MULTI-ACT A Collective Research Impact Framework and multi-variate models to foster the true engagement of actors and stakeholders in Health Research and Innovation Paola Zaratin, MULTI-ACT project coordinator on behalf of MULTI-ACT Consortium
  14. 14. “ACT LIKE AN ORGANIZATION, BUT THINK LIKE A MOVEMENT” TRANSFORMATIONAL MISSIONS: major strategic issues or challenges In such ventures the focus of the business moves beyond avoiding risks or enhancing reputation and toward improving its core value creation ability by addressing major strategic issues or challenges
  15. 15. FISM 2011/R/13 Rational design of new candidate compounds for multiple sclerosis treatment based on analysis of biological targets identified through genome wide association studies in Sardinia Professor F. Cucca
  16. 16. Link with other diseases Repurposing Research Strategy
  17. 17. Our Mission: To expedite development of effective disease modifying & symptom management therapies for progressive forms of MS

×